HIV protease inhibitors and insulin resistance: Lessons from in-vitro, rodent and healthy human volunteer models

Current Opinion in HIV and AIDS

Volumn 3, Issue 6, 2008, Pages 660-665

  Hruz, Paul W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Campus Box 8208 ^*  (United States)

Author keywords

Adipocytes; Drug toxicity; Euglycemic clamp; Glucose transport; Insulin resistance; Rodent model

Indexed keywords

ADIPOCYTOKINE; AMPRENAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOKINE; GLUCOSE TRANSPORTER 4; GS 8374; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PHOSPHONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PROTEOME; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; BINDING AFFINITY; CELL FUNCTION; DIABETES MELLITUS; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEPATITIS C; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MIXED INFECTION; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TARGET CELL; TREATMENT DURATION;

EID: 67649576658     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283139134     Document Type: Review

References (58)

1. Noor MA. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep 2007; 4:126-134.
2. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007; 61:463-472.
3. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007; 45 (Suppl 1):S19-S26.
4. Stankov MV, Behrens GM. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocr Metab Immune Disord Drug Targets 2007; 7:237-249.
5. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008; 10:61-70.
6. Barbaro G. Visceral fat as target of highly active antiretroviral therapyassociated metabolic syndrome. Curr Pharm Des 2007; 13:2208-2213.
7. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor, nonnucleoside reverse transcriptase inhibitor, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506-517.
8. Luzi L, Perseghin G, Tambussi G, et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003; 284:E274-E280.
9. Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005; 280:2238-2243.
10. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87:65-71.
11. Blumer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/ lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008; 22:227-236.
12. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139.
13. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
14. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119. In this study, the diagnosis of diabetes (as detected by elevated fasting or random blood glucose levels or both) was found to be significantly increased by current protease inhibitor and NRTI use. The contribution of traditional diabetes risk factors such as obesity can also be seen in this study.
15. Koster JC, Remedi MS, Qiu H, et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52:1695-1700.
16. Woerle HJ, Mariuz PR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52:918-925.
17. Schwarz JM, Lee GA, Park S, et al. Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004; 18:1852-1854.
18. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254.
19. Murata H, Hruz P, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16:859-863.
20. Nolte LA, Yarasheski KE, Kawanaka K, et al. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50:1397-1401.
21. Ben-Romano R, Rudich A, Torok D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003; 17:23-32.
22. Ben-Romano R, Rudich A, Tirosh A, et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 2004; 47:1107-1117.
23. Hamel FG, Fawcett J, Tsui BT, et al. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes Metab 2006; 8:661-668.
24. Schutt M, Meier M, Meyer M, et al. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia 2000; 43:1145-1148.
25. Kim RJ, Wilson CG, Wabitsch M, et al. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006; 14:994-1002.
26. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
27. Hertel J, Struthers H, Baird Horj C, Hruz PW. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 2004; 279:55147-55152.
28. Callebaut C, Stray K, Tsai L, et al. GS-8374, a novel phosphonate HIV protease inhibitor with potent in vitro antiretroviral activity, low metabolic toxicity, and favorable resistance profile. Antiviral Res 2007; 74:A27.
29. Yarasheki KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquired Immune Defic Syndr 1999; 21:209-216.
30. Schutt M, Zhou J, Meier M, Klein HH. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 2004; 183:445-454.
31. Dufer M, Neye Y, Krippeit-Drews P, Drews G. Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:583-590.
32. Neye Y, Dufer M, Drews G, Krippeit-Drews P. HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents. J Pharmacol Exp Ther 2006; 316:106-112.
33. Ben-Romano R, Rudich A, Etzion S, et al. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 2006; 11:1051-1060.
34. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500.
35. Hruz P, Murata H, Qiu H, Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002; 51:937-942.
36. Yan Q, Hruz PW. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005; 40:398-403.
37. Hruz PW, Yan Q. Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model. J Acquir Immune Defic Syndr 2006; 43:624-625.
38. Callebaut C, Yan Q, Koster J, et al. GS-8374, a novel HIV protease inhibitor, does not alter peripheral glucose disposal in a healthy rodent model system. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6 2008; Boston, Massachusetts; 2008. This study illustrates the utility of in-vitro screening of candidate protease inhibitors for their ability to influence glucose uptake prior to large and costly clinical trials.
39. CarperMJ, Cade WT, Cam M, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008; 294:E558-E567. The alterations in SOCS-1 signaling observed in chronically treated rats were confirmed by in-vitro studies in 3T3-L1 adipocytes. In addition to providing a model predisposed to diabetes, use of rodents allows the harvesting and analysis of tissues that are difficult to obtain from human volunteers.
40. Hruz PW, Yan Q, Struthers H, Jay PY. HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J 2008; 22:2161-2167.
41. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
42. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulinstimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
43. Lee GA, Mafong DD, Lo JC, et al. Ritonavir acutely induces insulin resistance in healthy normal human volunteers. Antivir Ther 2004; 9:L6.
44. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183-2190. This study combined with the others, done in healthy human volunteers, clearly demonstrates differences between individual HIV protease inhibitors in their ability to acutely induce insulin resistance. They also highlight the importance of the duration of HIV protease inhibitor exposure.
45. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660.
46. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
47. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ ritonavir in HIV-negative men. AIDS 2004; 18:641-649.
48. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
49. Kosmiski LA, Bacchetti P, Kotler DP, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab 2008; 93:216-224.
50. Kim MJ, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12:1273-1283.
51. Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006; 11:529-535.
52. Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008; 56:539-544. In using euglycemic clamps to measure peripheral insulin sensitivity, this study demonstrates both the reversibility of HIV protease inhibitor-mediated effects on glucose disposal and the favorable metabolic profile of atazanavir.
53. Masia M, Padilla S, Bernal E, et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 2007; 29:1448-1455.
54. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2005; 28:2289-2304.
55. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453.
56. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care 2007; 30:113-119.
57. Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, mid-western US outpatient population. Clin Infect Dis 2007; 44:726-734.
58. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.